By Nana O 
Mayo Clinic has announced the groundbreaking results of an innovative treatment approach that shows significant potential for improving overall survival in older patients diagnosed with newly diagnosed glioblastoma, while crucially preserving their quality of life. Glioblastoma, the most aggressive and lethal form of primary brain cancer, poses a formidable challenge due to its invasive nature and inherent resistance to conventional therapies. This devastating disease affects an estimated 14,500 individuals in the United States annually. The findings from Mayo Clinic’s phase 2, single-arm study, detailing this novel treatment, have been published in the esteemed journal The Lancet Oncology, marking a pivotal moment in the fight against this relentless cancer.
A Paradigm Shift in Glioblastoma Treatment for Seniors
The research, spearheaded by Dr. Sujay Vora, a radiation oncologist at Mayo Clinic, focused on a cohort of patients aged 65 and older newly diagnosed with World Health Organization (WHO) grade 4 malignant glioblastoma. The innovative treatment protocol involved a short-course, hypofractionated proton beam therapy regimen, augmented by the integration of advanced imaging techniques. This meticulous approach aimed to deliver precise radiation to the tumor while minimizing damage to the surrounding healthy brain tissue, a persistent challenge in traditional glioblastoma treatment.
The study’s outcomes are particularly encouraging. A remarkable 56% of participants were alive at the 12-month mark, with a median overall survival of 13.1 months. Dr. Vora emphasized the significance of these figures when compared to historical data: "As compared to prior phase 3 studies in an older population having a median survival of only six to nine months, these results are promising," he stated. "In some cases, patients with tumors that have favorable genetics lived even longer, with a median survival of 22 months. We are very excited about these results." This extended survival, coupled with the preservation of functional abilities, represents a substantial leap forward for a patient demographic often facing limited treatment options and a grim prognosis.
Understanding the Glioblastoma Challenge
Glioblastoma’s formidable nature stems from its aggressive infiltrative growth pattern. The cancer cells extend thread-like projections into healthy brain tissue, making complete surgical resection exceedingly difficult. Surgeons face a delicate balancing act: removing as much of the tumor as possible to reduce its bulk and impact, while simultaneously safeguarding critical brain regions responsible for vital functions such as motor control, speech, and cognition. Compounding these surgical challenges are the tumor’s inherent cellular heterogeneity and its remarkable ability to develop resistance to various therapeutic interventions, including chemotherapy and standard radiation.
Traditional radiation therapy, while a cornerstone in glioblastoma management, carries the inherent risk of collateral damage to adjacent healthy brain tissue. This can lead to a spectrum of debilitating side effects, impacting a patient’s neurological function and overall well-being. The Mayo Clinic’s pioneering study sought to circumvent these limitations by employing proton beam therapy, a highly advanced and targeted form of radiation treatment. This cutting-edge, non-surgical modality utilizes protons to precisely target and destroy cancer cells, thereby sparing surrounding healthy tissues from unnecessary radiation exposure.
Precision Targeting Through Advanced Imaging
A critical component of this innovative treatment was the sophisticated integration of advanced imaging technologies. Mayo Clinic investigators meticulously mapped the target area within the patient’s brain by combining the power of 18F-DOPA PET scans with contrast-enhanced MRI. This synergistic approach allowed for the precise identification of the most metabolically active and, therefore, the most aggressive regions of the glioblastoma.
"Combining advanced imaging allowed us to determine the most metabolically active, or aggressive, regions of the glioblastoma," explained Dr. Vora. This enhanced visualization enabled the radiation oncologists to focus the proton beam therapy with unparalleled accuracy, ensuring that the therapeutic dose was delivered precisely where it was needed most, while simultaneously minimizing exposure to surrounding healthy brain structures.
Accelerated Treatment, Extended Life
The hypofractionated nature of the proton beam therapy protocol was another significant advancement. Instead of the traditional three to six weeks of radiation treatment, patients in this study completed their therapy in a condensed timeframe of one to two weeks. This reduction in treatment duration offers a substantial benefit to patients, particularly older individuals who may experience greater fatigue and a diminished tolerance for prolonged medical interventions.
"The advanced imaging along with the proton beam therapy allowed us to be more focused with radiation and protect surrounding healthy brain tissue from the effects of radiation," Dr. Vora reiterated. "We were able to see that patients tolerated the treatments well and lived longer than we expected." The combination of precise targeting, reduced treatment duration, and improved patient tolerance collectively contributed to the study’s promising survival and quality of life outcomes.
This groundbreaking study represents the first clinical trial of its kind to investigate the use of short-course, hypofractionated proton beam therapy, augmented by advanced imaging such as 18F-DOPA PET and contrast-enhanced MRI, specifically for older patients (65 and above) newly diagnosed with glioblastoma.
Patient Testimonials: Hope and Gratitude
The impact of this innovative treatment is powerfully illustrated through the experiences of the study participants. Richard Casper, a patient from Arizona, lived nearly two years beyond his initial prognosis. His daughter, Susan Casper, shared her family’s profound gratitude: "We miss our dad dearly. We will forever be grateful for the extra time we had with our father. The time gave us a chance to make memories that will last us a lifetime. It was also important to my father to participate in this study in hopes of helping others fight glioblastoma." Richard Casper, who sadly succumbed to the disease in 2023, reported feeling remarkably well during his extended period, stating, "I feel great. If someone didn’t tell me I had the glioblastoma, I wouldn’t even know it."
Nadya El-Afandi, a wife and mother of four from St. Paul, Minnesota, diagnosed with glioblastoma in 2022, is another testament to the treatment’s efficacy. Fifteen months post-treatment, she exhibits no signs of glioblastoma recurrence. El-Afandi shared her positive experience: "I feel wonderful. I’ve had my fourth MRI, and we’re not seeing any return of the glioblastoma." Her remarkable recovery has allowed her to resume her normal activities, including a recent trip to Hawaii where she enjoyed snorkeling and hiking. "We are living on the edge of medical miracles, and we are riding that tide. There’s no cure for glioblastoma yet, but I’ve been able to take advantage of this medical opportunity, and it has given me a quality of life that is just outstanding," she added. El-Afandi’s focus remains on embracing life to its fullest: "I’m so grateful. Every day is the best day, and I’m going to enjoy every minute of it."
The Road Ahead: Larger Trials and Future Directions
While the results of this phase 2 study are exceptionally encouraging, Dr. William Breen, a radiation oncologist and principal investigator of the ongoing larger clinical trial, cautioned against premature conclusions. "Our goal is to transform the way we treat glioblastoma using shorter courses of radiation to minimize the burden on patients and their families and help them complete safe and effective treatment in a shorter amount of time," he stated. A larger, randomized clinical trial, known as SAGA (stereotactic ablative radiation treatment for glioblastoma), is currently underway at Mayo Clinic, encompassing patients from Arizona, Florida, and Minnesota. This trial aims to further validate the findings of the initial study and provide more definitive evidence regarding the safety and efficacy of this novel treatment approach.
"We are now adding another component that builds upon Dr. Vora’s work to help us best visualize the tumor," Dr. Breen added, indicating a continuous effort to refine and enhance the treatment protocol. The SAGA trial is designed to build upon the foundation laid by Dr. Vora’s work, incorporating further advancements in imaging and treatment delivery to optimize outcomes for glioblastoma patients.
Broader Implications and Funding
The implications of this research extend far beyond the immediate patient population. The successful development of a treatment that not only extends survival but also preserves quality of life for older adults with glioblastoma could significantly alter the treatment landscape for this devastating disease. By reducing the burden of prolonged treatment and minimizing debilitating side effects, this approach offers a more humane and patient-centered pathway forward.
The research was made possible through the generous support of the Mayo Clinic Marley Endowment Funds and the Lawrence W. and Marilyn W. Matteson Fund in Cancer Research, underscoring the critical role of philanthropic investment in driving medical innovation. As the SAGA trial progresses, the medical community will be keenly observing its outcomes, hopeful that this innovative proton beam therapy approach will become a new standard of care for older patients battling glioblastoma. The pursuit of a cure for glioblastoma remains ongoing, but these promising advancements offer a beacon of hope for patients and their families worldwide.